Sanofi (SNY.US) announced that second-generation myocardial globulin inhibitors have been approved for marketing in China

The Zhitong Finance App learned that on December 17, Sanofi (SNY.US) announced that the second-generation myocardial myosin inhibitor (CMI) Aficamten (Chinese product name: Xing Shuping) was approved for marketing by the National Drug Administration to treat adult patients with obstructive hypertrophic cardiomyopathy (HCM) with grade II-III cardiac function classification by the New York Heart Association (NYHA) to improve exercise capacity and symptoms.

Avcatec is a small molecule myocardial myosin inhibitor developed independently by Cytokinetics. The drug uses comprehensive chemical optimization to improve pharmacokinetic characteristics and reduce the number of active myosin production crossbridges in each cardiac cycle, thereby inhibiting myocardial overcontraction associated with hypertrophic cardiomyopathy. At the same time, the pharmacological properties of this treatment make the half-life shorter, only 3-4 days, and the optimal dose can be reached in 8 weeks.

In 2020, Cytokinetics granted Minxing Pharmaceutical an exclusive license to develop and commercialize Avcatec in Greater China. In 2024, Sanofi will acquire Avcatel's exclusive development and commercialization interests in Greater China from Minxing Pharmaceutical.

According to reports, afcatel tablets are potentially the “best in class” treatment in the field of hypertrophic cardiomyopathy. This approval marks that Avcatel tablets are an innovative drug that has achieved “world premiere” in China. China's approval comes before other countries and regions around the world, such as the US and the European Union.